The approval allows Jaypirca to be used as a first-line treatment for eligible patients. Jaypirca is the first and only FDA-approved non-covalent Bruton tyrosine kinase (BTK) inhibitor and is designed ...

“A new development in CLL treatment: Pirtobrutinib moves into the frontline. On October 2, 2026, the US FDA approved ...

Bengaluru, Oct 3 (PTI) More than 1,500 swimmers are set to take part in the second edition of the Asian Masters Swimming Championships to be held here from Sunday ...

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration has approved an expanded indication for Jaypirca (pirtobrutinib) to treat adult patients with ...

The FDA has approved pirtobrutinib (Jaypirca) monotherapy as a treatment for adults with previously untreated chronic ...

The Food and Drug Administration (FDA) has approved Jaypirca® (pirtobrutinib) for the treatment of adult patients with previously untreated chronic ...

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

Fugitive diamond businessman Mehul Choksi has dropped his multimillion-pound damages claim against the Indian govt ...

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...

The FDA expanded the approval of pirtobrutinib to include initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia with no known 17p deletion. Pirtobrutinib ...

FDA authorized frontline pirtobrutinib for previously untreated CLL/SLL without known 17p deletion, expanding use beyond its established relapsed/refractory setting after covalent BTK inhibition.